Multiple Myeloma: all 3,712 studies
Page 35 of 38. Open to participants first (752), then studies with results posted, then the rest; newest registration first within each.
- Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic CancerCompletedNCT00301951Phase 1
- Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic CancerWithdrawnNCT00301912Phase 2
- Assessing Free Immunoglobulin Light Chains in Patients With MyelomaCompletedNCT00301275
- A Randomized Trial of Human Growth Hormone (hGH) vs Placebo in Intensively Treated Haemato-Oncology Patients.CompletedNCT00300664Phase 2/3
- Safety Study of Parathyroid Hormone in Patients Needing Additional Stem Cell Mobilization.CompletedNCT00299780Phase 1
- Phase I Study of Sequential Cord Blood TransplantsCompletedNCT00299767Phase 1
- Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic CancerCompletedNCT00296023Not applicable
- Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic AnemiaStatus unknownNCT00295997Not applicable
- Safety and Efficacy of SDX-101 (R-Etodolac) in Patients With Relapsed or Refractory Multiple Myeloma (MM)TerminatedNCT00293111Phase 2
- Comparison of Pharmacokinetics and Pharmacodynamics of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Multiple MyelomaCompletedNCT00291538Phase 1
- Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic CancerTerminatedNCT00290628Not applicable
- Quality of Life in Patients With Multiple MyelomaCompletedNCT00290095
- Bortezomib in Treating Patients With Multiple Myeloma Who Have Undergone an Autologous Peripheral Blood Stem Cell TransplantCompletedNCT00288028Phase 1
- Caregiver Support in the Coping of Patients Who Are Undergoing a Donor Bone Marrow TransplantCompletedNCT00281814
- Caregiver Support in the Quality of Life of Patients Who Are Undergoing Donor Bone Marrow TransplantationCompletedNCT00281801
- The Effect of High Dose Simvastatine on Multiple MyelomaCompletedNCT00281476Phase 1/2
- Interferon Alfa in Treating Patients With Stage IV Solid Tumors, Lymphoma, or MyelomaCompletedNCT00276536Phase 1
- Trial of AVN-944 in Patients With Advanced Hematologic MalignanciesCompletedNCT00273936Phase 1
- The Effect of Epoetin Alfa on the Anemia of Patients With Selected Cancers Receiving ChemotherapyCompletedNCT00270166Phase 3
- The Effect of Epoetin Alfa on the Anemia of Patients With Multiple MyelomaCompletedNCT00270101Phase 3
- Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic CancerCompletedNCT00265837Phase 3
- Higher Frequency Zoledronic Acid in the Treatment of Multiple MyelomaCompletedNCT00263484Phase 2
- Paricalcitol and Zoledronate in Treating Patients With Relapsed or Refractory Multiple Myeloma or Other Plasma Cell DisordersTerminatedNCT00258258Phase 1
- Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell LeukemiaCompletedNCT00258245Phase 1
- Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and TolerabilityCompletedNCT00257114Phase 4
- Pazopanib (GW786034) In Subjects With Relapsed Or Refractory Multiple MyelomaCompletedNCT00256880Phase 2
- Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for CancerCompletedNCT00255749Phase 2
- Cyclophosphamide and/or Mycophenolate Mofetil With or Without Tacrolimus in Treating Patients Who Are Undergoing a Donor Bone Marrow or Peripheral Stem Cell Transplant for Hematologic CancerCompletedNCT00255710Phase 1
- Sorafenib in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00253578Phase 2
- G-CSF-Treated Donor Bone Marrow Transplant in Treating Patients With Hematologic DisordersTerminatedNCT00253552Not applicable
- Donor White Blood Cell Infusions and Interleukin-2 in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed Advanced Lymphoid CancerCompletedNCT00248430Phase 1/2
- TKI258 in Subjects With Refractory or Relapsed Multiple MyelomaTerminatedNCT00243763Phase 1
- Tipifarnib and Bortezomib in Treating Patients With Relapsed Multiple MyelomaTerminatedNCT00243035Phase 1/2
- Efficacy and Safety of Oral CEP-701 for the Treatment of Patients With Advanced Multiple MyelomaTerminatedNCT00242827Phase 2
- Open-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Bone Lesions Secondary to Multiple Myeloma.WithdrawnNCT00242528Phase 4
- A Phase II Study of Clofarabine in Patients With Relapsed or Refractory Multiple MyelomaTerminatedNCT00241371Phase 2
- Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast CancerCompletedNCT00237627Phase 1/2
- A Study of Peripheral Blood Progenitor Cells Mobilisation (PBPC) With VTP195183 Plus Granulocyte-Colony Stimulating Factor (G-CSF) Compared to Mobilisation With G-CSF AloneCompletedNCT00234169Phase 1/2
- Melphalan, Prednisone and Thalidomide Versus Melphalan and Prednisone in Elderly Myeloma PatientsCompletedNCT00232934Phase 3
- Safety, Efficacy, Dose-finding Study of a Monoclonal Antibody in Patients With Multiple MyelomaCompletedNCT00231166Phase 1
- Arsenic Trioxide, Thalidomide, Dexamethasone, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple MyelomaTerminatedNCT00227682Phase 2
- IFM 99-02 Thalidomide in MyelomaCompletedNCT00222053Phase 3
- Efficacy and Safety of Zoledronic Acid in Patients With Bone Metastases of Any Solid Tumors or Multiple MyelomaCompletedNCT00219258Phase 3
- Thalidomide to Patients With Previously Untreated Multiple MyelomaCompletedNCT00218855Phase 3
- An Extension Study to Provide Bortezomib to Patients With Relapsed or Refractory Multiple Myeloma Who Previously Participated in a Bortezomib Phase I/II Study and Who May Benefit From Re-Treatment With or Continuation of Bortezomib TherapyCompletedNCT00216697Phase 2
- Zoledronic Acid in the Management of Patients With Asymptomatic/Early Stage Multiple MyelomaTerminatedNCT00216151Phase 2
- FREE Study - Fracture Reduction EvaluationCompletedNCT00211211Phase 4
- The Optimal Timing of a Second Autologous Peripheral Blood Stem Cell Transplantation in Patients (<61 Years) With Multiple MyelomaCompletedNCT00207805Phase 3
- Tandem High Dose Melphalan Versus Triple Intermediate Dose Melphalan and Stem Cell Transplantation in Induction Phase and Prednisolone/IFN Versus IFN in Maintenance TherapyCompletedNCT00205764Phase 3
- Thalidomide/Dexamethasone vs MP for Induction Therapy and Thalidomide/Intron A vs Intron A for Maintenance TherapyCompletedNCT00205751Phase 2/3
- Liposomal Doxorubicin, Vincristine, & Dexamethasone Plus Arsenic Trioxide in Untreated Symptomatic Multiple MyelomaCompletedNCT00201695Phase 2
- IFM 2005-01: Velcade/Dexamethasone Versus Vincristine/Adriamycin (Doxorubicin)/Dexamethasone (VAD) for the Treatment of Patients With Multiple MyelomaCompletedNCT00200681Phase 3
- Comparison Between FDG-PET and MRI for the Assessment of Response to Intensive Chemotherapy in Multiple Myeloma Patients.TerminatedNCT00200668Not applicable
- Weekly Bortezomib (Velcade) in the Treatment of Patients With Refractory Multiple MyelomaCompletedNCT00193557Phase 2
- Arsenic Trioxide and Thalidomide in the Treatment of Refractory Multiple MyelomaCompletedNCT00193544Phase 2
- Vaccine Therapy for Multiple Myeloma Utilizing Idiotype-Pulsed Allogeneic Dendritic CellsCompletedNCT00186316Phase 1/2
- High Dose Sequential Therapy and Autologous Stem Cell Rescue for Multiple MyelomaCompletedNCT00186238Phase 2
- Cytokine Induced Killer Cells as Post-Transplant Immunotherapy Following Allogeneic Hematopoietic Cell TransplantationCompletedNCT00185757Phase 1
- Mixed Chimera Allogeneic Transplantation From Matched Unrelated Donors For The Treatment Of Multiple MyelomaCompletedNCT00185653Not applicable
- Thalidomide, Dexamethasone, and Clarithromycin in Treating Patients With Multiple Myeloma Previously Treated With TransplantCompletedNCT00182663Phase 2
- Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative DiseaseTerminatedNCT00176475Phase 1
- Clinical Implication of Bone Marrow Perfusion Patterns Imaged by Dynamic MRI in Multiple MyelomaStatus unknownNCT00166855Not applicable
- Protein Tyrosine Kinases (PTK) in Multiple MyelomaCompletedNCT00165347Phase 2
- Atorvastatin in MyelomaStatus unknownNCT00164086Phase 1
- A Novel Vaccine for the Treatment of MUC1-expressing Tumor MalignanciesWithdrawnNCT00162500Phase 2
- Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple MyelomaCompletedNCT00153933Phase 1
- Phase II Study of Biaxin, Revlimid, and Dexamethasone for Untreated Multiple MyelomaCompletedNCT00151203Phase 2
- Low-Intensity Preparation and Allogeneic Transplant in Patients With Cancers of the BloodCompletedNCT00146055Phase 2
- Adjuvant I.V. Iron Therapy During Erythropoetin Treatment of Anemic Patients With Lymphoproliferative Disorders.CompletedNCT00145652Phase 3
- Study of Low Intensity Conditioning and Immunotherapy for High-Risk Cancers of the BloodTerminatedNCT00143884Phase 2
- Study of Combination Therapy With VELCADE, Doxil, and Dexamethasone (VDd) in Multiple MyelomaCompletedNCT00135187Not applicable
- Study of Unrelated Cord Blood Transplantation Using Tacrolimus and SirolimusCompletedNCT00133367Phase 2
- Clinical Trial of PXD101 in Patients With Advanced Multiple MyelomaCompletedNCT00131261Phase 2
- Thalidomide, Cyclophosphamide, Oral Idarubicin and Dexamethasone (T-CID) in Patients With Multiple MyelomaStatus unknownNCT00124813Phase 2
- Arsenic Trioxide and Pamidronate in Treating Patients With Advanced Solid Tumors or Multiple MyelomaCompletedNCT00124605Phase 1
- Study of F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Known or Suspected Cancers of Low IncidenceCompletedNCT00123773Phase 2
- Trial of Plasma Exchange for Acute Renal Failure at the Onset of MyelomaCompletedNCT00120263Not applicable
- Ice Chips or Saline Mouth Rinse in Reducing or Preventing Mucositis in Patients Receiving Melphalan and Autologous Stem Cell Transplant for Multiple MyelomaCompletedNCT00118339Not applicable
- Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney FunctionCompletedNCT00118170Phase 1
- Velcade, Doxil, and Dexamethasone (VDd) as First Line Therapy for Multiple MyelomaCompletedNCT00116961Phase 2
- Vaccination in the Peripheral Stem Cell Transplant Setting for Multiple MyelomaCompletedNCT00116441Phase 1/2
- UARK 2003-41: A Study of High-Dose Density Therapy in Patients With Multiple MyelomaCompletedNCT00113932Phase 2
- Non-Myeloablative HLA-Matched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic MalignanciesTerminatedNCT00113828Phase 2
- Non-Myeloablative HLA-Mismatched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic MalignanciesTerminatedNCT00113646Phase 2
- Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple MyelomaCompletedNCT00113204Phase 1
- Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple MyelomaWithdrawnNCT00112879Phase 2
- UARK 2005-01 Study of Velcade, Thalidomide, and Dexamethasone (VTD) With or Without Adriamycin® in Relapsed/Refractory PatientsCompletedNCT00111748Phase 3
- VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Patients With Previously Untreated Multiple MyelomaCompletedNCT00111319Phase 3
- Campath-1H + FK506 and Methylprednisolone for GVHDCompletedNCT00109993Phase 2
- S0340 MRI and Fludeoxyglucose F18 PET in Diagnosing Solitary PlasmacytomaTerminatedNCT00109889Phase 2
- A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Advanced Multiple Myeloma (0683-004)TerminatedNCT00109109Phase 1
- Fenretinide in Treating Patients With Refractory or Relapsed Hematologic CancerCompletedNCT00104923Phase 1
- A Study of Motexafin Gadolinium for the Treatment of Relapsed or Refractory Multiple MyelomaCompletedNCT00096837Phase 2
- Tacrolimus and Mycophenolate Mofetil in Preventing Acute Graft-Versus-Host Disease in Patients With Advanced Hematologic Cancer Who Are Undergoing Donor Stem Cell TransplantationCompletedNCT00096096Phase 2
- Extension Study of the Efficacy and Safety of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple MyelomaCompletedNCT00095680Phase 2
- Study of Bortezomib and Revlimid™ for Patients Relapsing or Progressing on Total Therapy IICompletedNCT00093028Phase 3
- A Study of Doxil, Vincristine and Decadron (DVd) +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM)CompletedNCT00091624Phase 1
- Study of KIR-Ligand Mismatched Haplo-Identical Natural Killer Cells Transfused Before Autologous Stem Cell TransplantCompletedNCT00089453Phase 1
- Melphalan, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed, Previously Untreated Primary Systemic AmyloidosisCompletedNCT00089167Phase 2
- Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell TransplantationCompletedNCT00089037Phase 1/2